AwanHChauhanU (2017) Health Promotion and screening for people with an intellectual disability. InnovAiT10(3): 157–164. DOI: 10.1177/1755738016682982.
2.
BergougMDoudeauMGodinF, et al. (2020) Neurofibromin structure, functions and regulation. Cells9(11): 2365.
3.
CartonCEvansDGBlancoI, et al. (2023) ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. EClinicalMedicine56: 101818.
ChoiJAnSLimSY (2022) Current concepts of neurofibromatosis type 1: pathophysiology and treatment. Archives of Craniofacial Surgery23(1):6–16. DOI: 10.7181/acfs.2022.00633.
DoserKJepsenJKenborgL, et al. (2024) Neurocognitive functioning in adults with neurofibromatosis type 1 – a nationwide population-based study. Orphanet Journal of Rare Diseases19: 441. DOI: 10.1186/s13023-024-03454-w.
8.
FriedmanJM (1998) Neurofibromatosis 1. In: AdamMPFeldmanJMirzaaGM, et al. (editors) GeneReviews. Seattle, WA: University of Washington. pp. 1-44. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1109/ (accessed 28 April 2026)
9.
Hernandez-MartinADuat-RodriguezA (2016) An update on neurofibromatosis type 1: not just cafe-au-lait spots, freckling, and neurofibromas. An update. Part I. Dermatological clinical criteria diagnostic of the disease. Actas Dermo-Sifiliográficas107(6): 454–464.
10.
LegiusEMessiaenLWolkensteinP, et al. (2021) Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genetics in Medicine23(8): 1506–1513. DOI: 10.1038/s41436-021-01170-5.
11.
National Institutes of Health (NIH) Consensus Development Conference (1988) Neurofibromatosis. Conference statement. Archives of Neurology45(5): 575–578.
